Custom Skincare Formulation Brief FAQ
Data: Independent ingredient safety assessments consolidate toxicological evidence for cosmetic ingredients and give a formulator a citable basis for concentration decisions inside a development project.
Judgment: Ask the formulator which published safety references support the chosen actives at the intended use level, because a brief that fixes a concentration without supporting evidence creates a development risk that surfaces late as a reformulation.
Source: Cosmetic Ingredient Review (CIR) - CIR Ingredient Safety Assessments (2024)
Data: Advertising claims must be truthful and substantiated by evidence held before publication, which places the claim list inside the development brief rather than in the marketing plan that follows it.
Judgment: Put the claim list in the brief even when the wording is undecided, because the difference between a hydrating and a clinically tested product is a study and a timeline, and a formulator can only build for a claim that has been stated.
Source: U.S. FTC - Truth in Advertising and Claim Substantiation (2024)
Data: ISO 22716 defines documentation and control expectations at the cosmetics manufacturing step, which is the standard a finished product specification should be written against.
Judgment: Ask for the specification file formatted to a recognised manufacturing-practice basis, because a specification the next factory cannot read is not a transferable asset even when it is technically complete.
Source: ISO - ISO 22716 - Cosmetics Good Manufacturing Practices (2007)
| # | Anchor Text | URL | Source Institution | Report / Article Name | Year |
|---|---|---|---|---|---|
| 1 | cosmetic ingredient safety assessments | https://www.cir-safety.org/ | Cosmetic Ingredient Review (CIR) | CIR Ingredient Safety Assessments | 2024 |
| 2 | advertising substantiation rules | https://www.ftc.gov/news-events/topics/truth-advertising | U.S. FTC | Truth in Advertising and Claim Substantiation | 2024 |
| 3 | ISO cosmetics good manufacturing practices | https://www.iso.org/ | ISO | ISO 22716 - Cosmetics Good Manufacturing Practices | 2007 |
| 4 | FDA cosmetics programme | https://www.fda.gov/cosmetics | U.S. FDA | FDA Cosmetics Programme | 2024 |
What belongs in a custom skincare formulation brief?
Eight sections: product category and intent, sensory and texture target, ingredient direction including required actives and an exclusion list, intended claims, pack format and fill, target market, cost, volume and timeline constraints, and the documentation required on delivery. A brief missing the sensory target or the exclusion list is the most common cause of a rejected first sample. Two to three pages is enough; the goal is specificity rather than length, and a short brief with a measurable texture target develops faster than a long one without it.
How do you write a sensory target a formulator can reproduce?
Convert adjectives into behaviour. Instead of light, state that the product absorbs within a defined time on skin. Instead of rich, state higher viscosity and slower spread. Instead of natural, state no added fragrance plus a named exclusion list. Instead of non-greasy, name the oil phase and the intended finish. A formulator receiving a reproducible target selects the emulsifier system and oil phase deliberately; one receiving adjectives makes a reasonable choice and is wrong roughly half the time.
Why does the exclusion list matter so much?
Exclusions are the cheapest risk control in formulation and the least often written down. State the excluded ingredient classes, named sensitisers, animal-derived materials, restricted raw-material families, and restricted process aids. An exclusion list also protects the brand's claims, because a product marketed as free from a substance fails on the first ingredient audit if the brief never said to exclude it. Inclusions tell the formulator what to build; exclusions tell them what would make the product unsellable.
Should the brief name specific raw materials?
Name a material where the brand requires that specific one, and otherwise describe the function and leave the selection to the formulator. Prescribing every material removes the formulator's ability to substitute, and substitution is often where cost and stability improvements come from. A good brief names the required actives and their function, states the exclusions absolutely, and leaves the emulsifier, thickener, and preservative choice to the development team within the stated constraints.
What review points should the brief set?
Six: brief acceptance with written scope confirmation, first sample against the sensory and claim targets, revision and adjustment, stability programme start with a date and protocol, pack compatibility result, and specification issue with a confirmed document transfer. Setting the review points in the brief turns development into a scheduled project rather than an open-ended correspondence. It also creates the decision points where the brand can stop a direction that is drifting before another sample round is spent.
What documentation should arrive with the finished formula?
The specification sheet, the ingredient list with concentrations, the stability and compatibility reports, the certificate of analysis format, and the manufacturing parameters needed to reproduce the batch. Ask for the specification written to a recognised manufacturing-practice basis so the next factory can read it. A formula without a transferred specification file cannot be re-sourced, re-tested, or defended, so document transfer belongs in the brief from the first version rather than in a late negotiation. Sources: Cosmetic Ingredient Review, U.S. FTC truth-in-advertising, ISO 22716, U.S. FDA cosmetics programme.